In a study of more than 500 adults, Moderna’s BA.4/BA.5-targeted vaccine proved a “superior” response three months after inoculation, according to the Nov. 14 news release.
Pfizer has not indicated whether it is testing its modified booster for its effectiveness against BQ.1 and BQ.1.1, which currently account for 44.2 percent of U.S. cases, according to CDC data.
